US-based pharmaceutical and biotechnology company Pfizer Inc. (NYSE: PFE) announced on Friday detailed overall survival (OS) results from the Phase 2 MagnetisMM-3 study of ELREXFIO (elranatamab-bcmm) in patients with heavily pretreated relapsed or refractory multiple myeloma (RRMM).

The study demonstrated a median OS of 24.6 (95% CI, 13.4, NE) months in cohort A (n=123) of the pivotal single arm trial.

These data from MagnetisMM-3 were presented during a poster session (#932) at the European Hematology Association (EHA) Hybrid Congress in Madrid, Spain.

'These compelling overall survival data support the clinical benefit ELREXFIO has already demonstrated and its potential to be a transformative treatment option for people with multiple myeloma,' said Roger Dansey, M.D., chief development officer, Oncology, Pfizer. 'The latest results from MagnetisMM-3 reinforce the very promising efficacy observed with ELREXFIO in a relapsed or refractory setting, with deep and durable responses and although definitive conclusions cannot be drawn across studies, the longest reported median progression-free survival among B-cell maturation antigen bispecific antibodies.'

'People with relapsed or refractory multiple myeloma often have limited therapeutic options as their disease progresses due to treatment resistance, resulting in increasingly shorter remission and duration of response,' said MagnetisMM-3 clinical trial investigator Mohamad Mohty, M.D., Ph.D., professor of Haematology and head of the Hematology and Cellular Therapy Department at the Saint-Antoine Hospital and Sorbonne University, Paris, France. 'These impactful overall survival data are particularly encouraging given the very advanced patient population with characteristics associated with poorer outcomes.'